Breast Biomarkers

Biomarker	Assay Purpose	Drug(s)	Diagnostic Test	Test ID
PD-L1	Triple Negative Breast Cancer (TNBC)	Pembrolizumab	PDL1 Dako 22C3 PharmDX	PDL1TNBC22C3PEMBRO

Gastrointestinal Biomarkers

Biomarker	Assay Purpose	Drug(s)	Diagnostic Test	Test ID
PD-L1	Gastric, GEJ, esophageal adenocarcinoma; ESCC	Pembrolizumab, Nivolumab	PDL1 Dako 22C3 PharmDX	''PDL1UPPERGIMARCH2026''
Claudin 18.2	Gastric or GEJ adenocarcinoma	Zolbetuximab	VENTANA CLDN18 (43-14A) RxDx	BMCLAUDIN18

Gyne Biomarkers

Biomarker	Assay Purpose	Drug(s)	Diagnostic Test	Test ID
PD-L1	Cervical cancer (SCC and Adenocarcinoma)	Pembrolizumab	PDL1 Dako 22C3 PharmDX	''PDL1CERVIX''
CEP17 SISH	Ploidy Analysis	N/A	VENTANA Inform Chromosome 17 probe	''MOLARCEP17''

Head & Neck Biomarkers

Biomarker	Assay Purpose	Drug(s)	Diagnostic Test	Test ID
PD-L1	Advanced HNSCC	Pembrolizumab	PDL1 Dako 22C3 PharmDX	''PDL1HNSCC22C3PEMBRO''
PD-L1	Resectable HNSCC	Pembrolizumab as Neoadjuvant	PDL1 Dako 22C3 PharmDX	''PDL1HNSCCNEOADPEMBRO''

Lung Biomarkers

Biomarker	Assay Purpose	Drug(s)	Diagnostic Test	Test ID
PD-L1	NSCLC stage IIIb to IV	Pembrolizumab	PDL1 22C3	''PDL1NSCLCPEMBRO22C3''
PD-L1	NSCLC stage II to IIIA	Atezolizumab as Adjuvant	PDL1 SP263	''PDL1NSCLCATEZOSP263''